Exciting Developments from Cerevance in Parkinson’s Disease Research
Cerevance, a clinical-stage biopharmaceutical company dedicated to developing advanced therapies for neurological and psychiatric disorders, is preparing to showcase pivotal data at prominent upcoming international medical congresses. Their commitment to addressing the complexities of neurodegenerative diseases, such as Parkinson’s disease, makes these presentations highly anticipated within the medical community.
Highlights from Upcoming Presentations
At the forefront of the presentations is the Phase 2 ASCEND trial focused on solengepras, a monotherapy treatment for early-stage Parkinson’s disease. This trial's topline results will offer insights into this innovative approach, potentially marking a significant advancement for those affected by this condition.
Additionally, a first-look at data from a Phase 1 trial investigating a novel KCNK13 inhibitor will be presented. This inhibitor is designed to target neuroinflammation, a critical factor in various CNS diseases, and represents a promising avenue for therapeutic development.
Another key aspect of Cerevance’s presentations will be the proprietary NETSseq platform, which aims to identify novel therapeutic targets for neurodegenerative diseases. Through this advanced technology, Cerevance is paving the way for the discovery of treatments that address unmet medical needs in this field.
Details for the Oral Presentation at AD/PD™ 2025
The oral presentation at the International Conference on Alzheimer’s and Parkinson’s Diseases is eagerly anticipated. Below are the essential details:
- Title: Results of ASCEND: A Phase 2 Trial of Solengepras (CVN424) as an Investigational Monotherapy for Treatment of Early Parkinson’s Disease
- Presenter: Aaron L. Ellenbogen, DO, MPH
- Session Date/Time: April 1, 2025, at 1:15 p.m. CEST / 4:15 a.m. PT
Poster Presentations at AAN 2025
In addition to the oral presentation, Cerevance will feature several poster presentations at the American Academy of Neurology Annual Meeting. Here are the highlights:
- Title: NETSseq Identifies Novel Therapeutic Targets for Neurodegenerative Diseases (#3592)
- Presenter: Sagar Vaidya, M.D., Ph.D.
- Session Date/Time: April 6, 2025, at 11:45 a.m. PT
- Title: A First-in-Human Phase 1 Study to Investigate the Safety, Tolerability, and Pharmacokinetics of CVN293, an Investigational Inhibitor of KCNK13 Targeting NLRP3-Mediated Neuroinflammation (#3282)
- Presenter: Sagar Vaidya, M.D., Ph.D.
- Session Date/Time: April 8, 2025, at 8 a.m. PT
- Title: Solengepras (CVN424): A Novel GPR6 Inhibitor in Clinical Development as an Investigational Therapy for Parkinson’s Disease (#2892)
- Presenter: Kelvin L. Chou, M.D., FAAN
- Session Date/Time: April 9, 2025, at 8 a.m. PT
About Cerevance
Cerevance focuses on improving the treatment landscape for neurodegenerative and psychiatric disorders with cell type-specific therapies. Their NETSseq platform is central to their strategy, enabling the identification of therapeutic targets that are otherwise difficult to detect. Their flagship investigational drug, solengepras, has progressed to Phase 3 development and aims to deliver a groundbreaking, oral non-dopaminergic treatment for Parkinson’s disease.
In addition to solengepras, Cerevance is developing other investigational therapies, including CVN766, which targets the orexin 1 receptor, and CVN293, a selective oral inhibitor of KCNK13, aiming to address various neurological and metabolic disorders. Each of these innovative therapies represents a potential path forward in treating conditions often deemed difficult to manage, emphasizing Cerevance’s dedication to developing effective solutions.
For more information about their pioneering work, please visit www.cerevance.com and connect on platforms like LinkedIn and X.
Frequently Asked Questions
What new data will Cerevance present at the upcoming congresses?
Cerevance will present topline results from the Phase 2 ASCEND trial for solengepras, along with data from a Phase 1 KCNK13 inhibitor trial.
What is the significance of the NETSseq platform?
NETSseq helps identify novel therapeutic targets that are crucial for developing new treatments for neurodegenerative diseases.
Who are the key presenters at these events?
Key presenters include Aaron L. Ellenbogen, Sagar Vaidya, and Kelvin L. Chou, who will lead various sessions on their research findings.
What stages of development are Cerevance's therapies currently in?
Solengepras is in Phase 3 development, while CVN766 and CVN293 are in earlier investigative phases targeting different neurological conditions.
How can I learn more about Cerevance's work?
For more information, visit their official website, and follow their updates on professional networking platforms like LinkedIn and X.
